Mechanism
CD20 (obinutuzumab) + 5T4 (naptumomab estafenatox) + PD-L1 (durvalumab)
Assets acting on this target.
- Class
- Combination regimen: anti-CD20 monoclonal antibody + 5T4-targeted tumor-directed superantigen fusion protein (Fab-SEA/SEE) + anti-PD-L1 monoclonal antibody
- Pathway
- Multi-mechanism immune activation: B-cell/target-cell depletion, 5T4-directed T-cell superantigen activation, and PD-1/PD-L1-PD-1/CD80 checkpoint blockade
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.